LGM
Logos Global Management Portfolio holdings
AUM
$1.5B
1-Year Est. Return
197.64%
This Fund
S&P 500
1 Year Est. Return
+197.64%
AUM
$1.5B
AUM Growth
+$488M
(+48%)
Holding
80
Top Buys
| 1 | +$46.6M | |
| 2 | +$28M | |
| 3 | +$27.9M | |
| 4 |
Immunovant
IMVT
|
+$24.5M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$20.6M |
Top Sells
| 1 | +$57M | |
| 2 | +$47.5M | |
| 3 | +$21.8M | |
| 4 |
Verastem
VSTM
|
+$20.9M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$19.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
PepGen
PEPG
$428M
| – | – |
-750,000
|
|
||
|
77
Protagonist Therapeutics
PTGX
$5.76B
| – | – |
-300,000
|
|
||
78
Arcus Biosciences
RCUS
$2.52B
| – | – |
0
|
|
||
79
Scholar Rock
SRRK
$4.52B
| – | – |
-175,000
|
|
||
|
EPRX
80
Eupraxia Pharmaceuticals
EPRX
$414M
| – | – |
-900,000
|
|